Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

11/11/2021 | 07:01am EST

NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler.

Presentation Details:

Event: Jefferies London Healthcare Conference
Date: November 18, 2021
Time: 3 a.m. EST

Event: Piper Sandler 33rd Annual Healthcare Conference
Date: November 22, 2021
Time: 10 a.m. EST

A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.

Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.

The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.

The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds in development include PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates. The Phase 1 study of PN-235 is completed, and Janssen is expected to initiate a Phase 2 study in psoriasis in early 2022. The Phase 1 study with PN-232 is in progress, with study completion expected by mid-2022. Additional research in IBD is expected to initiate in 2022. 

Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-two-upcoming-healthcare-investor-conferences-301421775.html

SOURCE Protagonist Therapeutics, Inc.


ę PRNewswire 2021
All news about PROTAGONIST THERAPEUTICS, INC.
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021INSIDER SELL : Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
2021JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations